Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Catalys Pacific is a venture capital firm dedicated to healthcare innovation, founded with the mission of improving patient lives through the creation and development of biotech companies. Established with a significant presence in both Japan and the United States, the firm leverages a global network to access unique investment opportunities. Catalys Pacific is recognized as one of Japan's largest life sciences-focused investment firms, although specific quantitative metrics such as fund size or portfolio count are not disclosed.
The firm emphasizes transpacific partnerships to enhance its investment strategies, targeting both outbound and inbound opportunities. This approach aims to maximize therapeutic impact for patients while providing attractive returns for investors. Catalys Pacific's commitment to addressing unmet medical needs positions it as a compelling partner for organizations in the healthcare innovation space.
Catalys Pacific invests in early-stage biotech companies, particularly within the healthcare sector. The firm targets pre-seed, seed, and seed+ (extension) stages, focusing on innovative solutions that address significant medical challenges. Its investment strategy emphasizes transpacific partnerships, allowing the firm to tap into unique opportunities across North America and Asia.
The organization seeks to maximize therapeutic impact for patients while ensuring attractive returns for its investors. Catalys Pacific is particularly interested in companies that are developing novel therapies and solutions in the biotech space, aligning with its mission to improve patient outcomes through healthcare innovation.
Catalys Pacific's portfolio includes notable projects that reflect its focus on healthcare innovation:
These companies exemplify Catalys Pacific's commitment to investing in early-stage biotech firms that have the potential to make a significant impact on patient lives.
BT Slingsby, MD, PhD, MPH - Founder & Managing Director. He has extensive experience in healthcare and biotech, with a focus on innovative investment strategies.
Takeshi Takahashi, MBA - Managing Director. He brings a strong background in finance and investment management, particularly in the life sciences sector.
Jay Shepard - Venture Partner. He has a proven track record in venture capital and has led several successful investments in biotech.
Jon Congleton - Operating Partner. He specializes in operational support for portfolio companies, helping them scale effectively.
Neal Fowler, MBA - Operating Partner. He has significant experience in business development and strategic planning within the biotech industry.
Ashwin Ram, MD - Partner. He has a medical background and expertise in healthcare innovation.
Sandy Mong, MD - Partner. She focuses on healthcare investments and has a strong clinical background.
Ryutaro Shimazaki - Partner. He brings insights into the Asian market and its unique healthcare challenges.
Yoshiro Banno, MPH - Principal. He has experience in public health and its intersection with biotech.
Matt Sanders, MBA, JD, Tax LLM - Vice President. He specializes in legal and tax aspects of venture investments.
Yuki Makihira - Vice President. He focuses on investment analysis and market research.
Maki Haginoya - Vice President. She has a background in finance and investment strategy.
Ariel Miura - Analyst. He supports investment research and portfolio management.
Ryan Drant - Advisor. He provides strategic guidance based on his extensive industry experience.
Nobuo Hanai, PhD - Advisor. He has a strong academic background in life sciences.
Jonathan MacQuitty, PhD - Advisor. He specializes in biotech research and development.
Masato Iwasaki, PhD - Advisor. He brings expertise in drug development and regulatory affairs.
Seth H Z Fischer - Advisor. He has a background in venture capital and healthcare.
Norihiko Ishihara - Advisor. He provides insights into market trends and investment opportunities.
What are Catalys Pacific's investment criteria?
Catalys Pacific focuses on early-stage biotech companies within the healthcare sector, particularly those that are developing innovative solutions to address unmet medical needs. The firm invests at the pre-seed, seed, and seed+ stages, emphasizing transpacific partnerships to enhance its investment strategies.
How can I pitch to Catalys Pacific?
Founders interested in pitching to Catalys Pacific should prepare a detailed presentation that outlines their business model, market opportunity, and therapeutic impact. The firm values clear communication of how the proposed solution addresses significant medical challenges.
What makes Catalys Pacific different from other investors?
Catalys Pacific distinguishes itself through its strong focus on healthcare innovation and its emphasis on transpacific partnerships. This unique approach allows the firm to access a broader range of investment opportunities and insights into market dynamics across North America and Asia.
What is the geographic scope of Catalys Pacific's investments?
The firm operates globally, with a significant presence in both Japan and the United States. Catalys Pacific actively seeks investment opportunities in North America and Asia, leveraging its network to identify promising biotech companies.
What kind of post-investment involvement does Catalys Pacific have?
Catalys Pacific typically engages with its portfolio companies through board involvement and operational support. The firm aims to provide resources and mentorship to help founders navigate the challenges of scaling their businesses.
What is the typical check size for investments?
While specific check sizes are not disclosed, Catalys Pacific focuses on early-stage investments, which typically range from pre-seed to seed+ funding rounds.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.